Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference
Opthea (ASX/NASDAQ:OPT) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Frederic Guerard will present on January 15, 2025, at 5:15 PM PT, providing a business update that includes masked patient demographics and baseline characteristics from the sozinibercept Phase 3 wet AMD pivotal trials.
The clinical-stage biopharmaceutical company, focused on developing novel therapies for retinal diseases including wet age-related macular degeneration (wet AMD), will make its presentation available via webcast. The executive team will be available for one-on-one meetings from January 13-16, 2025. The presentation will be accessible through the company's website for 30 days following the event.
Opthea (ASX/NASDAQ:OPT) ha annunciato la sua partecipazione alla 43ª Conferenza Sanitaria Annuale J.P. Morgan a San Francisco. L'Amministratore Delegato Frederic Guerard presenterà il 15 gennaio 2025, alle 17:15 PT, fornendo un aggiornamento aziendale che include dati demografici e caratteristiche di base anonimizzati dei pazienti dai trial clinici pivotal di fase 3 con sozinibercept per la degenerazione maculare senile essudativa (wet AMD).
La compagnia biofarmaceutica in fase clinica, focalizzata sullo sviluppo di nuove terapie per le malattie retiniche tra cui la degenerazione maculare senile essudativa (wet AMD), renderà disponibile la sua presentazione tramite webcast. Il team dirigenziale sarà disponibile per incontri individuali dal 13 al 16 gennaio 2025. La presentazione sarà accessibile attraverso il sito web dell'azienda per 30 giorni dopo l'evento.
Opthea (ASX/NASDAQ:OPT) ha anunciado su participación en la 43ª Conferencia Anual de Atención Médica J.P. Morgan en San Francisco. El CEO Frederic Guerard presentará el 15 de enero de 2025, a las 17:15 PT, ofreciendo una actualización empresarial que incluye datos demográficos y características básicas enmascaradas de los pacientes de los ensayos clínicos pivotales de fase 3 con sozinibercept para la degeneración macular húmeda relacionada con la edad (wet AMD).
La compañía biofarmacéutica en etapa clínica, centrada en el desarrollo de nuevas terapias para enfermedades retinianas, incluyendo la degeneración macular húmeda relacionada con la edad (wet AMD), hará su presentación disponible a través de un webcast. El equipo ejecutivo estará disponible para reuniones uno a uno del 13 al 16 de enero de 2025. La presentación será accesible a través del sitio web de la empresa durante 30 días después del evento.
Opthea (ASX/NASDAQ:OPT)는 샌프란시스코에서 열리는 제43회 연례 J.P. Morgan 헬스케어 컨퍼런스에 참가한다고 발표했습니다. CEO Frederic Guerard는 2025년 1월 15일 오후 5시 15분 PT에 발표를 하여, 소지니버셉트 3상 습윤성 노인성 황반변성(wet AMD) 주요 시험에서의 환자 인구통계 및 기초 특성이 포함된 사업 업데이트를 제공할 예정입니다.
임상 단계에서의 생명공학 회사로서 습윤성 노인성 황반변성(wet AMD)을 포함한 망막 질환의 새로운 치료제를 개발하는 것을 목표로 하며, 발표는 웹캐스트를 통해 제공됩니다. 경영진 팀은 2025년 1월 13일부터 16일까지 개별 회의를 위해 참석할 것입니다. 발표 자료는 행사 이후 30일 동안 회사 웹사이트를 통해 접근할 수 있습니다.
Opthea (ASX/NASDAQ:OPT) a annoncé sa participation à la 43ème Conférence Annuelle de Soins de Santé J.P. Morgan à San Francisco. Le PDG Frederic Guerard fera une présentation le 15 janvier 2025 à 17h15 PT, fournissant une mise à jour sur l'entreprise comprenant des données démographiques masquées et des caractéristiques de base des patients provenant des essais pivot de phase 3 avec sozinibercept pour la dégénérescence maculaire humide liée à l'âge (wet AMD).
L'entreprise biopharmaceutique en phase clinique, axée sur le développement de nouvelles thérapies pour les maladies rétiniennes, y compris la dégénérescence maculaire humide liée à l'âge (wet AMD), mettra sa présentation à disposition via un webinaire. L'équipe dirigeante sera disponible pour des réunions individuelles du 13 au 16 janvier 2025. La présentation sera accessible sur le site web de la société pendant 30 jours suivant l'événement.
Opthea (ASX/NASDAQ:OPT) hat seine Teilnahme an der 43. jährlichen J.P. Morgan Healthcare-Konferenz in San Francisco angekündigt. CEO Frederic Guerard wird am 15. Januar 2025 um 17:15 Uhr PT präsentieren und ein Unternehmensupdate geben, das anonymisierte Patientendemografien und Basismerkmale aus den entscheidenden Phase-3-Studien zu sozinibercept für die feuchte altersbedingte Makuladegeneration (wet AMD) umfasst.
Das klinische Biopharmaunternehmen, das sich auf die Entwicklung neuartiger Therapien für Netzhauterkrankungen, einschließlich der feuchten altersbedingten Makuladegeneration (wet AMD), konzentriert, wird seine Präsentation über Webcast verfügbar machen. Das Führungsteam steht vom 13. bis 16. Januar 2025 für Einzelgespräche zur Verfügung. Die Präsentation wird 30 Tage nach der Veranstaltung über die Website des Unternehmens zugänglich sein.
- None.
- None.
Business update to include masked Phase 3 patient demographics and baseline characteristics
Presentation on Wednesday, January 15, 2025, 5:15 PM PT in San Francisco, California
MELBOURNE, Australia and PRINCETON, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Frederic Guerard, PharmD, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, January 15, 2025 at 5:15 PM PT.
Dr. Guerard will provide an update on the business, including masked patient demographics and baseline characteristics from the sozinibercept Phase 3 wet AMD pivotal trials. Opthea’s executive team will attend the conference and be available for one-on-one meetings January 13-16, 2025.
The live webcast and presentation will be accessible on the “Events & Presentations” section of the Company’s website at http://ir.opthea.com/, where the replay will be available for 30 days.
About Opthea
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.
To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.
Authorized for release to ASX by Frederic Guerard, PharmD, CEO
| Investor Inquiries PJ Kelleher LifeSci Advisors, LLC Email: pkelleher@lifesciadvisors.com Phone: 617-430-7579 | Media Inquiries Silvana Guerci-Lena NorthStream Global Partners Email: silvana@nsgpllc.com |
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com
Source: Opthea Limited
FAQ
When will Opthea (OPT) present at the J.P. Morgan Healthcare Conference 2025?
What will be included in Opthea's (OPT) J.P. Morgan Healthcare Conference presentation?
How can investors access Opthea's (OPT) J.P. Morgan Healthcare Conference presentation?
What are the dates for one-on-one meetings with Opthea's (OPT) executive team at the J.P. Morgan conference?
What type of clinical trials is Opthea (OPT) currently conducting?
